Reference entry — NOT a sellable lane, and NOT approved anywhere. Retatrutide is the sharpest "demand-outruns-approval" case in the register: genuinely spectacular trial data, but an investigational drug with zero legal sellable pathway. The "research-use-only" retatrutide sold gray-market is unregu
Retatrutide is Eli Lilly's investigational triple GLP-1/GIP/glucagon agonist ("triple-G"), which in Phase 3 (TRIUMPH-1) produced the deepest weight loss of any obesity candidate to date (~28–30%). The evidence is genuinely strong and trending toward approval — but it is not approved anywhere, the Phase 3 programme is still completing, and the "research-use-only" retatrutide sold online is unregulated and not the studied product.
- Everywhere — investigational, NOT approved. No FDA, no EMA, no approved prescription pathway; all legitimate use is within Lilly's clinical trials. - Gray market: "research-use-only" retatrutide is widely sold but unapproved and unregulated — unknown purity, sterility, and dosing accuracy; it is not the trial compound. - This venture: not a sellable lane — an investigational drug; gray-market sa
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (fast-moving — re-check TRIUMPH-2/-3 readouts and any regulatory filing).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.